Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adhesion of Buprenorphine Transdermal Delivery System 40 µg/h vs 20 µg/h in Healthy Volunteers
NCT02431624Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine in pain (2 arms), sponsored by Mundipharma. Primary endpoint: Patch Adhesion score at 7 days. Started Mar 2015; status: completed.
02
Drugs
buprenorphine
03
Conditions
pain
Beyond the preview
Go deeper on NCT02431624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431624.